Antibodies to proteinase-3 and myeloperoxidase in systemic vasculitis


Aim. To investigate occurrence and diagnostic significance of antibodies to proteinase-3 (aPR-3) and myeloperoxidase (aMPO) in systemic vasculitis (SV).
Material and methods. A total of 98 patients with different forms of SV were examined: nonspecific aortoarteritis (NAA, n = 18), nodular polyarteritis (NP, n = 18), Wegener granulomatosis (WG, n = 20), obliterating thrombangiitis (ОТ, n - 21), and hemorrhagic vasculitis (HV, n = 21). Eight patients with primary antiphospholipid syndome (PAPS) and 20 donors comprised a control group. aPR-3 and aMPO were detected by solid-phase enzyme immunoassay using kits ORGenTec Diagnostica GmbH.
Results. aPR-3 were detected in 1 (5.6%) patient with NP and in 3 (14.3%) patients with HV. aPR3 were detected in 13 (65%) of 20 patients with WG being significantly more frequent not only vs controls (0%) but in some forms of SV and PAPS (p < 0.05). Mean aPR-3 level in 13 WG patients was significantly higher than in 4 patients (1 with NP and 3 with HV) the sera of whom also contained aPR-3. 84.6% patients with WG had higher concentrations of aPR-3, this is significantly more frequently than in the comparison group. In NP and HV these autoantibodies were encountered in the serum only in moderate or low concentrations in patients with high clinicolaboratory activity of the disease. In WG patients there was no correlation between aPR-3 presence, form of the disease and basic clinical manifestations, but mean values of index of clinical activity of vasculitis were significantly higher in patients with aPR-3 than in those free of them. Concentration ofaPR-3 in an active phase of the disease was significantly higher than in patients in remission. Moreover, aPR-3 were detected in 83.3% cases in active vasculitis and in 37.5% patients without it. Detection ofaPR-3 in WG group was associated with mean sensitivity and good specificity. In examination of the patients in an active phase specificity rose but sensitivity fell. Optimal results were obtained in estimation of aPR-3 level. Thus, in moderate or high concentration, aPR-3 have good sensitivity and high specificity for diagnosis of WG, in a high titer (> 15 U/ml) they are highly sensitive and specific for this vasculitis. aMPO were detected in 1 of 18 patients with NP, in 1 of 21 - with ОТ, in 3 of 21 - with HV and in 2 of 21 - w,th NAA. None patients with WG or PAPS had aMPO. aMPO were detected in NP and HV in high activity of inflammation. Part of the patients had affected kidneys.
Conclusion. Thus, WG is characterized by the presence and high concentration ofaPR-3. In the latter case aPR-3 have high (100%) sensitivity and specificity for diagnosis of WG. Detection ofaPR-3 can be used as an additional laboratory test for diagnosis of WG and estimation of its activity.


  1. Bacon P. A. Vasculitis - then and now. In: Ansell В. М., Bacon P. A., Lie J. Т., Yazici H., eds. The vasculitides. London; 1996. 1-20.
  2. Hewins P., Cohen Tervaert J. W., Savage С. О. S., Kallenberg С. G. M. Is Wegener's granulomatosis an autoimmune disease? Curr. Opin. Rheum. 2000; 12: 3-10.
  3. Sayne D. Update on the European Vasculitis Study Group trials. Curr. Opin. Rheum. 2001; 13: 48-55.
  4. Breedveld F. C., Daha M. R. Vasculitis mechanisms of injury. In: Ansell B. M., Bacon P. A., Lie J. Т., Yazici H., eds. The vasculitides. London; 1996. 39-47.
  5. Schonermarck U., Lamprecht P., Csernok E., Gross W. L. Prevalence and spectrum of rheumatic diseases associated with proteinase 3-antioneutrophil cytoplasmic antibodies (ANCA) and myeloperoxidase-ANCA. Rheumatology 2001; 40: 178-184.
  6. Бекетова Т. В., Семенкова Е. Н., Насонов Е. Л. Клиническое значение обнаружения антител к антигенам цитоплазмы нейтрофилов при гранулематозе Вегенера. Тер. арх. 1995; 10: 24-27.
  7. Насонов Е. Л., Бекетова Т. В., Баранов А. А. и др. Антинейтрофильные цитоплазматические антитела при системных васкулитах. Клин. мед. 1992; 11-12: 21-27.
  8. Тищенко В. А., Бекетова Т. В., Семенкова Е. Т. и др. Антинейтрофильные цитоплазматические антитела при гранулематозе Вегенера: анализ с помощью иммуноферментного и иммунофлюоресцентного методов. Тер. арх. 1995; 5: 48-51.
  9. Ishikawa К. Diagnostic approach and proposed criteria for the clinical dignosis of Takayasu's arteriopathy. J. Am. Coll. Cardiol. 1988; 12: 964-972.
  10. Horsch A. K., Borsch S., More H. Beitrad zur diagnose der thromboangiitis obliterans (morbus v. Winiwarter-Buerger) durch den Nachweis von anti-elestinanti korpern. Vasa 1985; 14(1): 5-9.
  11. Lugmani R. A., Bacon P. A., Moots R. J. et al. Birmingham vasculitis activity score (BVAS) in systemic necrotising vasculitis. Quart. J. Med. 1994; 87: 671-678.
  12. Lupi-Herrera E., Sanchez-Torres G., Marchushamer J. et al. Takayasu's arteritis. Clinical study of 107 cases. Am. Heart J. 1977; 93: 94-103.
  13. Wilson W. A., Gharavi A. E., Koike T. et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthr. and Rheum. 1999; 42: 1309-1311.
  14. Gross W. L., Csernok K., Flesch B. "Classic" anti-neutrophil cytoplasmic autoantibodies (cANCA), "Wegener's autoantigen" and their immunopathogenic role in Wegener's granulomatosis. J. Autoimmun. 1993; 6: 171-184.
  15. Hauschild S., Csernok E., Schmitt W. H. et al. Antineutrophil cytoplasmic antibodies in systemic polyarteritis nodosa with and without hepatitis В virus infection and Churg-Straus syndrome - 62 patiens. J. Rheumatol. 1994; 21: 173-174.
  16. Dagenais P. P., Daple G., Fernades M. F. et al. ANCAs in patients with Takayasu's arteritis. Clin. Exp. Immunol. 1993; 93 (suppl. 1): 34.
  17. Girard Т., Mahr A., Noel L.-H. et al. Are antineutrophil cytoplasmic antibodies a marker predictive of relapse in Wegener's granulomatosis? A prospective study. Rheumatology 2001; 40: 147-151.
  18. Cohen Tervaert J. W. C., van der Woude F. J., Fauci A. S. et al. Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch. Intern. Med. 1989; 149: 2461-2465.
  19. Rider P., Wener M. H., French J. et al. Autoantibody production in Kawasaki syndrome. Clin. Exp. Rheumatol. 1993; 11: 445-449.
  20. Schellong S. M., Schulze M., Welte T. et al. Clinical profile of ANCA-associated diseases. Vasa 1992; 35 (suppl.): 60-63.
  21. Strunz H. P., Csernok E., Gross W. L. Incidence and disease association of a proteinase 3-antineutrophil cytoplasmic antibody idiotype (5/7) whose antiidiotype inhibits proteinase 3antineutrophil cytoplasmic antibody antigen binding activity. Arthr. and Rheum. 1999; 40: 135-142.
  22. Jennette J. C., Falk R. J., Andrassy K. et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthr. and Rheum. 1994; 37: 187-192.
  23. Brons R. H., de Jong M. С. J. M., de Boer N. K. et al. Detection of immune deposits in skin lesions of patients with Wegener's granulomatosis. Ann. Rheum. Dis. 2001; 60: 1097-1102.
  24. Boomsma M. M., Stegeman С. A., van der Leij et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels. Arthr. and Rheum. 2000; 43: 2025-2033.



Abstract - 97


Article Metrics

Metrics Loading ...


  • There are currently no refbacks.

Copyright (c) 2020 Baranov A.A., Kirdyanov S.Y., Beketova T.V., Bazhina O.V., Guryeva M.S., Abaitova N.E.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:


© 2018 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies